Catalyst Event
Akeso Inc (9926) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/25/2026, 12:00:00 AM
On March 25, 2026, Akeso announced it received NMPA clearance to initiate Phase II clinical trials for two ADCs, AK146D1 and AK138D1, advancing its 'IO 2.0 + ADC 2.0' strategy. Medium importance estimated due to potential for >5% price impact from clinical progress, scheduled.
Korean Translation
2026년 3월 25일, 'IO 2.0 + ADC 2.0' 전략의 일환으로 항체-약물 접합체(ADC)인 AK146D1 및 AK138D1에 대한 2상 임상시험 개시를 중국 국가약품감독관리국(NMPA)으로부터 승인받았다고 발표함. 임상 진전에 따른 5% 이상의 주가 영향이 예상되어 Medium 등급으로 분류함. 예정됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM